What is Saxenda?
Saxenda is a weight-loss injection containing liraglutide, a GLP-1 receptor agonist developed by Novo Nordisk. It is specifically approved for weight loss and obesity management. You administer the injection daily through a subcutaneous injection, similar to insulin. Saxenda was the first GLP-1 medication approved for weight loss and has had the longest track record since 2015. In SCALE studies, patients achieved average weight loss of 8-10%, with more than 63% losing at least 5% of their weight.